State Street
NVLN

State Street’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

State Street’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-219,361
Closed -$768K – 3823
2018
Q1 		$768K Buy
219,361
+27,000
+14% +$114K ﹤0.01% 3380
2017
Q4 		$600K Buy
192,361
+73,524
+62% +$353K ﹤0.01% 3425
2017
Q3 		$835K Buy
118,837
+29,669
+33% +$238K ﹤0.01% 3411
2017
Q2 		$821K Buy
+89,168
New +$859K ﹤0.01% 3365

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

State Street's NVLN Position: Q2 2018 in Review

State Street sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 219,361 shares — an estimated $768K sold.

State Street first reported a position in NVLN in Q2 2017 and held it in 4 quarters. The position peaked at $835K in Q3 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • State Street reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • State Street sold 219,361 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $768K.
  • State Street first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 4 quarters.
  • State Street's Novelion Therapeutics Inc. Common Shares position peaked at $835K in Q3 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on State Street's 13F filing for Q2 2018, filed 14 Aug 2018.